Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study

被引:60
作者
Mannu, Gurdeep S. [1 ]
Wang, Zhe [1 ]
Broggio, John [2 ]
Charman, Jackie [2 ]
Cheung, Shan [2 ]
Kearins, Olive [2 ]
Dodwell, David [1 ]
Darby, Sarah C. [1 ]
机构
[1] Univ Oxford, Nuffield Dept Populat Hlth, Richard Doll Bldg,Old Rd Campus, Oxford OX3 7LF, England
[2] Publ Hlth England, Natl Canc Registrat & Anal Serv, Birmingham, W Midlands, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 369卷
基金
英国医学研究理事会;
关键词
RISK; OUTCOMES; DCIS; RADIOTHERAPY; PREDICTORS; RECURRENCE; DIAGNOSIS; TRIAL;
D O I
10.1136/bmj.m1570
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To evaluate the long term risks of invasive breast cancer and death from breast cancer after ductal carcinoma in situ (DCIS) diagnosed through breast screening. DESIGN Population based observational cohort study. SETTING Data from the NHS Breast Screening Programme and the National Cancer Registration and Analysis Service. PARTICIPANTS All 35 024 women in England diagnosed as having DCIS by the NHS Breast Screening Programme from its start in 1988 until March 2014. MAIN OUTCOME MEASURES Incident invasive breast cancer and death from breast cancer. RESULTS By December 2014, 13 606 women had been followed for up to five years, 10 998 for five to nine years, 6861 for 10-14 years, 2620 for 15-19 years, and 939 for at least 20 years. Among these women, 2076 developed invasive breast cancer, corresponding to an incidence rate of 8.82 (95% confidence interval 8.45 to 9.21) per 1000 women per year and more than double that expected from national cancer incidence rates (ratio of observed rate to expected rate 2.52, 95% confidence interval 2.41 to 2.63). The increase started in the second year after diagnosis of DCIS and continued until the end of follow-up. In the same group of women, 310 died from breast cancer, corresponding to a death rate of 1.26 (1.13 to 1.41) per 1000 women per year and 70% higher than that expected from national breast cancer mortality rates (observed:expected ratio 1.70, 1.52 to 1.90). During the first five years after diagnosis of DCIS, the breast cancer death rate was similar to that expected from national mortality rates (observed:expected ratio 0.87, 0.69 to 1.10), but it then increased, with values of 1.98 (1.65 to 2.37), 2.99 (2.41 to 3.70), and 2.77 (2.01 to 3.80) in years five to nine, 10-14, and 15 or more after DCIS diagnosis. Among 29 044 women with unilateral DCIS undergoing surgery, those who had more intensive treatment (mastectomy, radiotherapy for women who had breast conserving surgery, and endocrine treatment in oestrogen receptor positive disease) and those with larger final surgical margins had lower rates of invasive breast cancer. CONCLUSIONS To date, women with DCIS detected by screening have, on average, experienced higher long term risks of invasive breast cancer and death from breast cancer than women in the general population during a period of at least two decades after their diagnosis. More intensive treatment and larger final surgical margins were associated with lower risks of invasive breast cancer.
引用
收藏
页数:13
相关论文
共 29 条
[1]  
[Anonymous], 1980, CLASSICAL METHODS AN
[2]   Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery [J].
Benson, John R. ;
Wishart, Gordon C. .
LANCET ONCOLOGY, 2013, 14 (09) :E348-E357
[3]   Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence [J].
Bleyer, Archie ;
Welch, H. Gilbert .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (21) :1998-2005
[4]   Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS) [J].
Cheung, Shan ;
Booth, Mary E. ;
Kearins, Olive ;
Dodwell, David .
BREAST, 2014, 23 (06) :807-811
[5]  
Correa C, 2010, J NATL CANCER INST M, V2010, P162
[6]   Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial [J].
Cuzick, Jack ;
Sestak, Ivana ;
Pinder, Sarah E. ;
Ellis, Ian O. ;
Forsyth, Sharon ;
Bundred, Nigel J. ;
Forbes, John F. ;
Bishop, Hugh ;
Fentiman, Ian S. ;
George, William D. .
LANCET ONCOLOGY, 2011, 12 (01) :21-29
[7]   Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study [J].
Duffy, Stephen W. ;
Dibden, Amanda ;
Michalopoulos, Dimitrios ;
Offman, Judith ;
Parmar, Dharmishta ;
Jenkins, Jacquie ;
Collins, Beverley ;
Robson, Tony ;
Scorfield, Suzanne ;
Green, Kathryn ;
Hall, Clare ;
Liao, Xiao-Hui ;
Ryan, Michael ;
Johnson, Fiona ;
Stevens, Guy ;
Kearins, Olive ;
Sellars, Sarah ;
Patnick, Julietta .
LANCET ONCOLOGY, 2016, 17 (01) :109-114
[8]   Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women [J].
Elshof, Lotte E. ;
Schaapveld, Michael ;
Schmidt, Marjanka K. ;
Rutgers, Emiel J. ;
van Leeuwen, Flora E. ;
Wesseling, Jelle .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) :553-563
[9]   Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study [J].
Elshof, Lotte E. ;
Tryfonidis, Konstantinos ;
Slaets, Leen ;
van Leeuwen-Stok, A. Elise ;
Skinner, Victoria P. ;
Dif, Nicolas ;
Pijnappel, Ruud M. ;
Bijker, Nina ;
Rutgers, Emiel J. Th. ;
Wesseling, Jelle .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (12) :1497-1510
[10]   The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ [J].
Francis, A. ;
Fallowfield, L. ;
Rea, D. .
CLINICAL ONCOLOGY, 2015, 27 (01) :6-8